Literature DB >> 8464707

Splicing choice from ten variant exons establishes CD44 variability.

C Tölg1, M Hofmann, P Herrlich, H Ponta.   

Abstract

The enormous heterogeneity of the surface protein designated CD44 is in part due to posttranslational modification, and in part due to differential splicing. Alternative splicing occurs within one particular region encoding the extracellular portion of the protein. Comparison of various cDNA clones with different 'inserts' in this variable region with sequences of genomic clones from the mouse has revealed the existence of at least ten exons from which sequences are chosen by alternative splicing. Various combinations of these exons account for the tremendous heterogeneity of CD44 molecules expressed in different tissues, and in progressing tumor cells. The existence of different isoforms of CD44 suggests a broad spectrum of yet unknown physiologic functions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464707      PMCID: PMC309286          DOI: 10.1093/nar/21.5.1225

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  32 in total

1.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain.

Authors:  D G Jackson; J Buckley; J I Bell
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

2.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family.

Authors:  I Stamenkovic; M Amiot; J M Pesando; B Seed
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

3.  A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins.

Authors:  L A Goldstein; D F Zhou; L J Picker; C N Minty; R F Bargatze; J F Ding; E C Butcher
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

4.  Structural heterogeneity of human Pgp-1 and its relationship with p85.

Authors:  M B Omary; I S Trowbridge; M Letarte; M F Kagnoff; C M Isacke
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

5.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells.

Authors:  W G Carter; E A Wayner
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

6.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

7.  Structural variants of human T200 glycoprotein (leukocyte-common antigen).

Authors:  S J Ralph; M L Thomas; C C Morton; I S Trowbridge
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

8.  Lymphocyte specific heterogeneity in the rat leucocyte common antigen (T200) is due to differences in polypeptide sequences near the NH2-terminus.

Authors:  A N Barclay; D I Jackson; A C Willis; A F Williams
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

9.  Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells.

Authors:  S Jalkanen; R F Bargatze; J de los Toyos; E C Butcher
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

10.  Differential exon usage involving an unusual splicing mechanism generates at least eight types of NCAM cDNA in mouse brain.

Authors:  M J Santoni; D Barthels; G Vopper; A Boned; C Goridis; W Wille
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  72 in total

1.  Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines.

Authors:  Anjali Shiras; Arti Bhosale; Anjali Patekar; Varsha Shepal; Padma Shastry
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 2.  Cancer stem cells as a potential therapeutic target in breast cancer.

Authors:  Mingzhi Zhang; Zhaoming Li; Xudong Zhang; Yu Chang
Journal:  Stem Cell Investig       Date:  2014-07-16

3.  Endothelial adhesion of synchronized gastric tumor cells changes during cell cycle transit and correlates with the expression level of CD44 splice variants.

Authors:  Anton Oertl; Jens Castein; Tobias Engl; Wolf-Dietrich Beecken; Dietger Jonas; Richard Melamed; Roman A Blaheta
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

4.  Expression patterns of CD44 adhesion molecule in testicular germ cell tumors and normal testes.

Authors:  H Miyake; I Hara; K Yamanaka; K Gohji; S Arakawa; S Kamidono
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 5.  Cancer stem cell detection and isolation.

Authors:  Meysam Moghbeli; Faezeh Moghbeli; Mohammad Mahdi Forghanifard; Mohammad Reza Abbaszadegan
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 6.  Forms and functions of CD44.

Authors:  G Borland; J A Ross; K Guy
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

7.  Influence of intron length on alternative splicing of CD44.

Authors:  M V Bell; A E Cowper; M P Lefranc; J I Bell; G R Screaton
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

8.  Epithelial Ovarian Cancer and Cancer Stem Cells.

Authors:  Amr A Soliman; Alaa A Elzarkaa; Eduard Malik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Inferring alternative splicing patterns in mouse from a full-length cDNA library and microarray data.

Authors:  Hiromi Kochiwa; Ryosuke Suzuki; Takanori Washio; Rintaro Saito; Hidemasa Bono; Piero Carninci; Yasushi Okazaki; Rika Miki; Yoshihide Hayashizaki; Masaru Tomita
Journal:  Genome Res       Date:  2002-08       Impact factor: 9.043

Review 10.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.